135 filings
Page 2 of 7
8-K
wq9naekn
23 Mar 23
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
4:07pm
8-K
er5wvsa638kfuby2
6 Jan 23
Entry into a Material Definitive Agreement
5:30pm
424B5
y892kjur1ongws0qiez
6 Jan 23
Prospectus supplement for primary offering
5:28pm
8-K
xeks hpc8zajs
18 Nov 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
hhn8050rqejb5v5qdgf
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
5xc9gz97d3es y4e3je
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
77ow6oxqxmw3fh150z0i
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
agng22869za0yixffp
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
c1ib1y 5ujfxvnmf2
24 May 22
Submission of Matters to a Vote of Security Holders
5:01pm
DEFA14A
2p7iv1pfu r0
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
etgiqallqy t7n7
16 May 22
Additional proxy soliciting materials
6:32pm
DFAN14A
4tzbhfz
16 May 22
Additional proxy materials by non-management
2:04pm
8-K
58pvhrep
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm
DFAN14A
qzaw3a972e 8wxe
12 May 22
Additional proxy materials by non-management
2:06pm
DEFA14A
m0tps2f2
11 May 22
Additional proxy soliciting materials
4:49pm
DEFA14A
ugmb2 06aq
9 May 22
Additional proxy soliciting materials
4:32pm
DEFA14A
gw8n5foq
5 May 22
Additional proxy soliciting materials
4:00pm